Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of ropeginterferon alfa-2b in Chinese patients with polycythemia vera resistant or intolerant to hydroxyurea
CTR20211664Phase 2Active
- Sponsor
- PharmaEssentia
- Start
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ropeginterferon alfa-2b in polycythemia vera (PV), sponsored by PharmaEssentia. Started Oct 2021; status: active.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on CTR20211664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211664.